Tirzepatide Drug Interactions: A Clinician's Guide From Reconciliation to Surgery

Why tirzepatide interactions work differently

Most interaction checks focus on enzymes, transporters, and protein binding. Tirzepatide asks a different set of questions. It is a dual GIP and GLP-1 receptor agonist given as a once-weekly subcutaneous injection, so its interaction risks come mostly from what it does to the body. You'll see two main patterns. The first is pharmacodynamic: additive effects on glucose lowering and appetite. The second is indirect: slowed gastric emptying can change when and how much of an oral drug gets absorbed.

That distinction matters most for patients on drugs with a narrow therapeutic window, where a small shift in exposure can mean a meaningful change in effect. Before you prescribe, pull up the current Mounjaro or Zepbound prescribing information from Eli Lilly and read the drug interaction, pharmacokinetic, and warnings sections together. Label language gets updated, so the version you read today is the one to document.

Medications with additive hypoglycemia risk

Insulin is the first category to review. The label advises that when tirzepatide is combined with insulin or an insulin secretagogue, a lower dose of the insulin or secretagogue may be needed to reduce hypoglycemia risk. Basal and prandial doses don't behave the same way, so look at the glucose log, not just the dose on the chart.

Sulfonylureas such as glipizide and glimepiride carry the most clinically relevant additive risk. Patients who eat less or skip meals after starting tirzepatide may be especially vulnerable, so ask about appetite changes at every visit.

Metformin carries a lower individual hypoglycemia risk when used alone, and it is often already part of the regimen. SGLT2 inhibitors have a different profile. Their main concerns involve volume depletion and ketone production, particularly when intake drops or vomiting occurs.

Patient education is the most inexpensive safety step you have. Patients should recognize shakiness, sweating, confusion, or sudden hunger as possible low blood sugar, and they should carry a fast-acting glucose source at all times. The ADA's Standards of Care in Diabetes, 2025 edition, Section 9, covers pharmacologic approaches to glycemic treatment and is a solid reference for these decisions.

Oral medications and slowed gastric emptying

When the stomach empties more slowly, an oral drug may reach the small intestine later and at a different rate. For most medications, that's a minor issue. For time-sensitive drugs, it can matter. The label notes this potential effect on oral drug absorption, so it belongs in your reconciliation notes, not in a footnote.

Levothyroxine is the example most clinicians worry about. Because small absorption changes can shift TSH, consider rechecking TSH after starting tirzepatide or after a dose change. Current endocrinology guidance on monitoring intervals is the right place to set the schedule for each patient.

Other time-sensitive oral drugs, including some anticonvulsants and certain antibiotics, deserve case-by-case review rather than a blanket rule. Ask whether the drug has a narrow therapeutic index, whether a delayed dose could cause harm, and whether a blood level can be measured.

On timing, keep it practical. Ask patients to write down when they take each oral medicine relative to their injection day. A written dosing timeline, the kind TirzeBlog encourages readers to keep, usually works better than memory during the first weeks after each dose change.

Hormonal contraception and pregnancy planning

The label addresses oral hormonal contraceptives directly. It advises patients who use them to switch to a non-oral method or add a barrier method for a defined period after starting tirzepatide and after each dose escalation. Read the exact duration in the current label and quote it in your note rather than relying on memory.

Reduced contraceptive exposure is a real clinical concern. A patient who skips backup protection during that window can become pregnant without planning to. Document the counseling, the method the patient chose, and the teach-back you completed together.

For pregnancy planning, the label recommends discontinuing tirzepatide before a planned pregnancy. Start that conversation early, because the timing of discontinuation shapes the whole plan.

Some patients prefer non-oral or intrauterine methods. These options aren't required, but they can simplify things for people who want fewer steps to remember. The CDC's U.S. Medical Eligibility Criteria for Contraceptive Use is the reference to check for method-specific questions.

Surgery, anesthesia, and procedures

Delayed gastric emptying raises a theoretical concern about aspiration during general anesthesia. Retained gastric contents may increase that risk, which is why the perioperative plan needs a deliberate owner.

Guidance from anesthesia and gastroenterology societies on holding GLP-1 and dual agonists has changed over time, and it continues to evolve. Earlier advice often called for a blanket hold before elective procedures. Newer multisociety recommendations lean toward individualized assessment, and some include liquid diet strategies before the procedure. Check the ASA's current guidance and the latest multisociety document before you finalize a hold plan.

Coordinate early with the surgeon, anesthesiologist, and prescriber. Decide who gives the hold instructions, in writing, and who makes the call on the day if the patient reports nausea, vomiting, bloating, or abdominal pain. Those symptoms can change anesthesia planning, so the team should know before induction.

Document the plan in the chart: the date of the last dose, the hold instructions given, the symptom screen, and who was notified. Tell the patient the same thing in plain language and provide it in writing. Ask patients to bring their questions about timing to the pre-op visit, and consider using a written list, the kind TirzeBlog suggests preparing ahead of time, so nothing gets rushed in the moment.

Building a monitoring plan and what patients can bring

Start with a medication reconciliation at baseline and again at every dose escalation. Ask about prescription drugs, over-the-counter products, herbal remedies, and supplements, since each one can affect glucose, absorption, or GI tolerance. A history that stops at the pharmacy printout misses a lot.

Tailor your labs and clinical checks to the medicines on the list. Glucose matters if the patient takes glucose-lowering agents. TSH matters with levothyroxine. Renal function and hydration status deserve attention whenever GI losses occur, because dehydration can affect the kidneys. The label also warns about pancreatitis and gallbladder disease, so ask about those symptoms too.

Red flags need a clear path to prompt contact. Severe abdominal pain, persistent vomiting, dizziness or fainting, and symptoms of low blood sugar should all trigger a call or an urgent visit. Give patients a phone number and a plain explanation of when to seek emergency care.

Ask patients to bring the following to each visit:

• A complete medication list with doses and strengths, including anything bought off the pharmacy shelf.
• The timing of each drug relative to the weekly injection, with a note on which ones are taken with food.
• All supplements, herbal products, and vitamins, with the brand names from the bottles.
• Recent glucose readings, symptom notes, and written questions for the prescriber.

A consistent log makes these visits faster and more accurate. Patients can keep one using the TirzeBlog resources page as a starting point, then review what goes in it with their prescriber.

This post is for information only. Dosing, holding, and monitoring decisions belong to the treating clinician, who knows the patient's full history.

FAQ

Can tirzepatide affect levothyroxine absorption?

The label notes that delayed gastric emptying may affect absorption of oral medications. Because levothyroxine is a common concern, many clinicians consider rechecking TSH after starting tirzepatide or changing the dose. Discuss timing and monitoring with your prescriber.

Does tirzepatide make birth control less effective?

The label advises patients using oral hormonal contraceptives to switch to a non-oral method or add a barrier method for a defined period after starting and after each dose escalation. Check the current label for the exact duration and document the counseling.

Should tirzepatide be held before surgery?

Guidance on holding GLP-1 and dual agonists has changed over time. The surgeon, anesthesiologist, and prescribing clinician should decide together, based on the latest society recommendations and the patient's GI symptoms on the day of the procedure.

Can metformin be used alongside tirzepatide?

Metformin carries a lower individual hypoglycemia risk when used alone, and it is often combined with other agents. Dosing still depends on kidney function and GI tolerance, so review those factors with your prescriber.

Sources

• Mounjaro (tirzepatide) Prescribing Information, Eli Lilly
• Zepbound (tirzepatide) Prescribing Information, Eli Lilly
• Standards of Care in Diabetes, 2025, Section 9: Pharmacologic Approaches to Glycemic Treatment, American Diabetes Association
• American Society of Anesthesiologists, practice guidance and news on GLP-1 receptor agonists
• CDC, U.S. Medical Eligibility Criteria for Contraceptive Use
• Institute for Safe Medication Practices (ISMP)